Management Team

Pavel HametPavel Hamet OQ, MD, PhD, FRCP(C),FRSM, FAHA, FCAHS, is founder, President and Chief Scientific Officer at Medpharmgene. Dr. Pavel Hamet is recognized internationally for his contribution to the field of diabetes, hypertension and genetics and is a member of the management of the largest-ever clinical trial in diabetes called ADVANCE (Lancet 2007, N Engl J Med 2008, Diabetes Care 2009) which is the source of the clinical data for Prognomix Inc. Dr. Hamet is the Canada Research Chair in Predictive Genomics. He is Professor of Medicine at the Université de Montréal, Adjunct Professor of Experimental Medicine at McGill University, and Visiting Professor at the First Faculty of Medicine at Charles University, Prague, Czech Republic. He founded and directed the Centre Hospitalier de l’Université de Montréal’s Research Centre (CRCHUM) from 1996 to 2006. He is currently Chief of Gene Medicine services at the CHUM as well as CEO at Prognomic Inc. Born in the Czech Republic, Dr. Hamet received his Doctorate in Medicine in 1967 from Charles University, a PhD in Experimental Medicine from McGill University in 1972, and a CSPQ in Endocrinology from Université de Montréal in 1974. He is a Fellow of the Canadian Academy of Health Sciences since 2004. Dr. Hamet is the author or co-author of over 500 scientific publications and holds several international patents. His major scientific contributions are in the areas of hypertension, diabetes and cardiovascular diseases, using approaches that range from bench to bedside to population health. Active in many societies, he is current President of the International Society of Pathophysiology. He was President of the Canadian and Quebec Hypertension Societies and General-Secretary of the International Society of Hypertension. He has received many honors, including the Harry Goldblatt Award from the American Heart Association (1990), Honorary Professor at the Shanghai II Medical University in China (1994), the J.E. Purkyne Golden Medal by the Czech Academy of Sciences (1994), the Distinguished Scientist Award from the Canadian Society for Clinical Investigation and the Achievement Award from the Canadian Cardiovascular Society (1996), the Wilder Penfield Award from the Government of Québec (2001), Honorary Member of the Czech Medical Academy, and the Michel Sarrazin Prize by the Club de recherches cliniques du Québec, the Canadian Hypertension Society Distinguished Service Award (2005). He is a member of the Academy of Great Montrealers (2006). In 2008, Dr Hamet was named as an Officer of the Ordre national du Québec and he received the Okamoto Award by the Japan Vascular Disease Research Foundation, the Masaryk Award from the Czech and Slovak Society in Canada and an award from the Russian Society of Cardiology and the Russian Antihypertensive league and received from the CHUM Fundation «le Prix Hommage» to underline his remarkable career (2009). He is associate-editor of the Journal of Hypertension and member of Collège International de Recherche Servier. Since 2010 he is a member of the Board of Directors of the Société francophone du diabète.

Marie-Josée GuertinMarie-Renée Guertin, RN (registered nurse) is Senior Clinical Research Associate at Medpharmgene. She is a registered nurse, member of OIIQ since 1985 and she followed the micro Program of superior studies in pharmaceutical development Université Laval-Québec. Mme Guertin has 10 years of experience in Clinical research and monitoring experience across Canada in various private and public clinical research organizations. She acts as the Regional Coordinator for the ADVANCE-ON Study. - canadian online casinos